胸腺肽α1围手术期应用对肝癌患者T细胞亚群的作用

The effects of thymic peptide α1 on T lymphocyte subsets of hepatoma patient during perioperative period

目的:探讨胸腺肽α1围手术期应用对肝癌患者细胞亚群的影响。方法:选取45例可切除肝癌患者,按手术大小分为治疗组(23例)和对照组(22例),治疗组术后当天、第3、第5d皮下注射胸腺肽α14mg,观察两组术前、术后第1、4、7d外周血T淋巴细胞CD3+、CD4+、CD8+、CD4+/CD8+分子的变化。结果:对照组术后CD3+、CD4+、CD4+/CD8+降低(CD4+、CD4+/CD8+术后1、4、7d与术前相比P<0.05),CD8+升高(术后1、4、7d与术前相比P<0.05),以第4d明显。治疗组CD3+、CD4+/CD8+术后第1、7d比较有统计学差异(P<0.05)。两组间比较,CD4+、CD4+/CD8+治疗组大于对照组(术后第1、4、7d均P<0.05),CD8+试验组小于对照组(术后第1、4、7d均P<0.05);CD3+试验组大于对照组(术后第4、7dP<0.05)。结论:手术对肝癌患者术后T淋巴细胞免疫功能抑制,胸腺肽对T淋巴细胞免疫功能有较好的保护作用。

Objective： To investigate the effects of thymic peptide α1 on T lymphocyte subsets of hepatoma patient during perioperative period. Methods： 45 patients whose livers can be resected were divided into treatment group （23 cases） and control group （22 cases） respectively. Patients in treatment group were given 14mg thymic peptide α1 through hypodermic injection at 0, 3rd, and 5th day after operation. CD3^＋, CD4^＋, CD8^＋, and CD4^＋/CD8^＋ were detected before operation and at 1, 4, and 7 day after operation for both groups. Results： In control group, CD3^＋, CD4^＋, and CD4^＋/CD8^＋ decreased （CD4^＋ and CD4^＋/CD8^＋ decreased at 1, 4, and 7 day after operation compared with pre-operation, P〈0.05）. CD8^＋ upregulated after operation compared with preoperation （P〈0.05）, especially at the 4th day. In treatment group, at the I st and 7th day, CD3^＋ and CD4^＋/CD8^＋ were different statistically （P〈0.05）, however, CD4^＋ and CD4^＋/CD8^＋ upregulated compared with control group （P〈0.05）, CD8^＋ decreased after operation （P〈0.05）. Level of CD3^＋ in treatment group was higher than that of control group at the 4th and 7th day after operation （P〈0.05）. Conclusions： T lymphocyte immune function of liver cancer patients is inhibited after operation. Thymic peptide α1 is benefit on protecting T lymphocyte immune function.